Newsfiscal.ai
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at SITC 2026 Annual Meeting
· Published
Article summary
Elicio Therapeutics announced it will present new data from its Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…